Publicaciones en colaboración con investigadores/as de Charles University in Prague (7)

2023

  1. Labetalol and soluble endoglin aggravate bile acid retention in mice with ethinylestradiol-induced cholestasis

    Frontiers in Pharmacology, Vol. 14

2021

  1. High soluble endoglin levels affect aortic vascular function during mice aging

    Journal of Cardiovascular Development and Disease, Vol. 8, Núm. 12

2020

  1. Long term effects of soluble endoglin and mild hypercholesterolemia in mice hearts

    PLoS ONE, Vol. 15, Núm. 5

  2. Soluble endoglin as a potential biomarker of nonalcoholic steatohepatitis (Nash) development, participating in aggravation of nash-related changes in mouse liver

    International Journal of Molecular Sciences, Vol. 21, Núm. 23, pp. 1-19

2019

  1. High soluble endoglin levels regulate cholesterol homeostasis and bile acids turnover in the liver of transgenic mice

    Life Sciences, Vol. 232

2018

  1. Soluble endoglin and hypercholesterolemia aggravate endothelial and vessel wall dysfunction in mouse aorta

    Atherosclerosis, Vol. 271, pp. 15-25

2017

  1. High soluble endoglin levels do not induce changes in structural parameters of mouse heart

    Heart and Vessels, Vol. 32, Núm. 8, pp. 1013-1024